Dogwood Therapeutics Stock Performance
| DWTX Stock | 2.93 0.02 0.69% |
The firm shows a Beta (market volatility) of 0.6, which means possible diversification benefits within a given portfolio. As returns on the market increase, Dogwood Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Dogwood Therapeutics is expected to be smaller as well. At this point, Dogwood Therapeutics has a negative expected return of -1.03%. Please make sure to confirm Dogwood Therapeutics' maximum drawdown, as well as the relationship between the daily balance of power and relative strength index , to decide if Dogwood Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Dogwood Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 0.69 | Five Day Return (1.01) | Year To Date Return (30.90) | Ten Year Return (99.30) | All Time Return (99.30) |
Last Split Factor 1:25 | Last Split Date 2024-10-09 |
1 | Disposition of 2161 shares by Sealbond Ltd of Dogwood Therapeutics, subject to Rule 16b-3 | 11/28/2025 |
2 | Acquisition by Gendreau Roger Michael of 150000 shares of Dogwood Therapeutics, at 6.14 subject to Rule 16b-3 | 12/04/2025 |
3 | What hedge fund activity signals for Dogwood Therapeutics Inc. stock - 2025 Sector Review Smart Swing Trading Alerts - DonanmHaber | 12/19/2025 |
4 | Whats Driving the Market Sentiment Around Dogwood Therapeutics Inc | 12/24/2025 |
5 | Dogwood Therapeutics Becomes Most Actively Discussed Biotech Stock Among Retail Traders After Stunning 370 percent Surge - MSN | 01/06/2026 |
6 | Dogwood Therapeutics, Inc. Announces Financing of up to 26.8 Million to Progress Halneuron Through Phase 2b Development | 01/12/2026 |
7 | Dogwood Therapeutics outlines 2026 plans for pain pipeline - The Globe and Mail | 01/21/2026 |
8 | Dogwood Therapeutics Announces 50 percent Enrollment in Ongoing Halneuron Phase 2b Trial, Top Line Results Anticipated in Q3 2026 | 02/02/2026 |
9 | Warrant approval could dilute Dogwood Therapeutics holders - Stock Titan | 02/13/2026 |
10 | Dogwood Therapeutics Receives Buy Rating from HC Wainwright | 02/20/2026 |
| Begin Period Cash Flow | 3.3 M | |
| Total Cashflows From Investing Activities | 3.8 M |
Dogwood Therapeutics Relative Risk vs. Return Landscape
If you would invest 621.00 in Dogwood Therapeutics on November 22, 2025 and sell it today you would lose (328.00) from holding Dogwood Therapeutics or give up 52.82% of portfolio value over 90 days. Dogwood Therapeutics is currently does not generate positive expected returns and assumes 6.3298% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of stocks are less volatile than Dogwood, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Dogwood Therapeutics Target Price Odds to finish over Current Price
The tendency of Dogwood Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.93 | 90 days | 2.93 | about 83.49 |
Based on a normal probability distribution, the odds of Dogwood Therapeutics to move above the current price in 90 days from now is about 83.49 (This Dogwood Therapeutics probability density function shows the probability of Dogwood Stock to fall within a particular range of prices over 90 days) .
Dogwood Therapeutics Price Density |
| Price |
Predictive Modules for Dogwood Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Dogwood Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Dogwood Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Dogwood Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Dogwood Therapeutics is not an exception. The market had few large corrections towards the Dogwood Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Dogwood Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Dogwood Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.82 | |
β | Beta against Dow Jones | 0.60 | |
σ | Overall volatility | 1.51 | |
Ir | Information ratio | -0.14 |
Dogwood Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Dogwood Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Dogwood Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Dogwood Therapeutics generated a negative expected return over the last 90 days | |
| Dogwood Therapeutics has high historical volatility and very poor performance | |
| Dogwood Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (12.35 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Dogwood Therapeutics generates negative cash flow from operations | |
| Dogwood Therapeutics has a poor financial position based on the latest SEC disclosures | |
| About 75.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: Dogwood Therapeutics Receives Buy Rating from HC Wainwright |
Dogwood Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Dogwood Stock often depends not only on the future outlook of the current and potential Dogwood Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Dogwood Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1 M | |
| Cash And Short Term Investments | 14.8 M |
Dogwood Therapeutics Fundamentals Growth
Dogwood Stock prices reflect investors' perceptions of the future prospects and financial health of Dogwood Therapeutics, and Dogwood Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Dogwood Stock performance.
| Return On Equity | -9.31 | ||||
| Return On Asset | -0.42 | ||||
| Current Valuation | 195.47 M | ||||
| Shares Outstanding | 29.73 M | ||||
| Price To Book | 1.35 X | ||||
| EBITDA | (12.25 M) | ||||
| Net Income | (12.35 M) | ||||
| Total Debt | 15.59 M | ||||
| Book Value Per Share | (14.42) X | ||||
| Cash Flow From Operations | (8.79 M) | ||||
| Earnings Per Share | (25.59) X | ||||
| Market Capitalization | 93.36 M | ||||
| Total Asset | 94.31 M | ||||
| Retained Earnings | (73.82 M) | ||||
| Working Capital | 13.37 M | ||||
About Dogwood Therapeutics Performance
Evaluating Dogwood Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Dogwood Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Dogwood Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.66) | (0.70) | |
| Return On Capital Employed | (0.15) | (0.16) | |
| Return On Assets | (0.13) | (0.12) | |
| Return On Equity | (0.22) | (0.23) |
Things to note about Dogwood Therapeutics performance evaluation
Checking the ongoing alerts about Dogwood Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Dogwood Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Dogwood Therapeutics generated a negative expected return over the last 90 days | |
| Dogwood Therapeutics has high historical volatility and very poor performance | |
| Dogwood Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (12.35 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Dogwood Therapeutics generates negative cash flow from operations | |
| Dogwood Therapeutics has a poor financial position based on the latest SEC disclosures | |
| About 75.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: Dogwood Therapeutics Receives Buy Rating from HC Wainwright |
- Analyzing Dogwood Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Dogwood Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Dogwood Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Dogwood Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Dogwood Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Dogwood Therapeutics' stock. These opinions can provide insight into Dogwood Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Dogwood Stock Analysis
When running Dogwood Therapeutics' price analysis, check to measure Dogwood Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dogwood Therapeutics is operating at the current time. Most of Dogwood Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dogwood Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dogwood Therapeutics' price. Additionally, you may evaluate how the addition of Dogwood Therapeutics to your portfolios can decrease your overall portfolio volatility.